Brief: SynAct Pharma Q1 Sales SEK 0
31/05/2024 06:30
May 31 (Reuters) - SynAct Pharma Q1 cash flow from operating activities SEK -11.189 million. * Q1 adjusted EPS SEK -0.7 * Q1 net income SEK -24.906 million * Q1 operating expenses SEK 25.706 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development